Company intelligence / Profile preview

Denovo Biopharma

San Diego, California, USAdenovobiopharma.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

Denovo Biopharma has achieved a major breakthrough in treatment-resistant depression with its biomarker-guided Phase 2b trial of DB104 (liafensine), meeting all major endpoints. The company’s lead oncology program DB102 (enzastaurin) has reached pivotal Phase 3 trials for DLBCL and GBM. Its pipeline includes eight late-stage drugs addressing unmet needs in oncology and CNS diseases.

Therapeutic areas: OncologyNeurology
Modalities: small moleculesgene therapy-based drugsrecombinant proteins/large molecules
Industry: Biotech

Drug pipeline

5 assets

enzastaurin

4 more assets in the full pipeline.

Partnerships

Aytu BioPharma for DB102 development/licensing for rare genetic diseases such as vascular Ehlers-Danlos syndromeJiangsu Wuzhong Pharmaceutical Group for endostatin rights acquisition outside China

Beyond the preview

Go deeper on Denovo Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Denovo Biopharma.